NAD+ Supplementation for Brain Aging: Separating Hype From Emerging Evidence

NAD+ — a coenzyme central to energy metabolism, DNA repair, and cellular signaling — declines measurably in the brain with age. This decline is thought to contribute to impaired mitochondrial function, reduced neuronal resilience, and the pathological processes underlying Alzheimer's disease and other neurodegenerative conditions. Restoring NAD+ has therefore become one of the most discussed targets in longevity and brain-health research.

This forum article in Trends in Endocrinology & Metabolism, authored by Wang, Zhang, and Fang from the University of Oslo, provides a critical but constructive appraisal of the NAD+ augmentation field as it applies specifically to brain aging. The authors synthesize preclinical findings — which are consistently encouraging — alongside a growing but still limited body of human clinical evidence.

The review identifies several unsettled challenges that complicate interpretation of the existing literature. First, measurement validity: current techniques for assessing brain NAD+ in living humans remain imprecise, making it difficult to confirm whether supplements actually raise brain levels. Second, blood-brain barrier penetration: it is not yet established that oral NAD+ precursors (NMN, NR, niacin) reliably increase NAD+ in brain tissue rather than just peripheral tissues. Third, dosing and trial design: optimal doses, supplementation duration, and target populations remain poorly defined, and existing clinical trials vary considerably in these parameters.

The authors also note important conflicts of interest among researchers in the field — including lead author Fang himself, who discloses commercial ties to NAD+ supplement companies — which adds to the need for independent replication and rigorous trial design.

For clinicians and health-conscious individuals, the paper's message is nuanced: the biological rationale for NAD+ augmentation in brain aging is solid, early human data are promising, but the field is not yet at the point of confident clinical recommendations. Priorities for future research include validated brain NAD+ biomarkers, randomized trials with cognitive endpoints, and better mechanistic understanding of brain delivery.